Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when NVCR files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsNovoCure reports Q1 2026 financial results
Filed April 30, 2026 · Period ending April 30, 2026 · ~1 min read
Key Changes
-
high
NovoCure issued a press release on April 30, 2026 announcing financial results for the quarter ended March 31, 2026. Specific metrics are contained in the attached press release.
Item 2.02 verify on EDGAR → -
medium
The 8-K filing itself contains no financial details; all Q1 2026 performance data is in the separate press release (Exhibit 99.1).
8-K: Exhibits verify on EDGAR →
Summary
NovoCure filed an 8-K on April 30, 2026 to announce its first quarter 2026 financial results. The company issued a press release the same day detailing performance for the three months ended March 31, 2026, though the 8-K body itself does not include specific revenue, earnings, or operational metrics. This is a standard quarterly earnings disclosure required under Item 2.02 of Form 8-K.
Retail investors should review the full press release (Exhibit 99.1) for actual Q1 numbers, including revenue growth, net income or loss, and any updated guidance for 2026. Watch for management commentary on Optune adoption trends and any pipeline updates in the accompanying earnings call, as these will signal whether NovoCure is meeting commercialization milestones for its tumor treating fields technology.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Item 2.02 — Results of Operations and Financial Condition filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On April 30, 2026, the Company issued a press release announcing certain financial results for the quarter ended March 31, 2026.
NovoCure disclosed its financial results for the first quarter ended March 31, 2026, through a press release issued on April 30, 2026. The actual financial metrics are contained in the attached press release (Exhibit 99.1), which is not included in this 8-K body text.
Event · Item 9.01 — Financial Statements and Exhibits
NovoCure filed an 8-K attaching a press release dated April 30, 2026; no material business event disclosed in the filing body.
Show 1 minor / wording change
Added in current filing · view on EDGAR →
Exhibit No.Description 99.1 Press Release of NovoCure Limited, dated April 30, 2026
NovoCure attached a press release dated April 30, 2026 as Exhibit 99.1. The 8-K body does not describe the content of the press release, so the nature of the disclosure cannot be determined from this filing alone.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 8, 2026 · How we verify